CAR-T CELL THERAPY: MANUFACTURING CHALLENGES AND COST CONSIDERATIONS
Main Article Content
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has produced durable remissions in some patients with refractory B-cell cancers, yet each dose is a bespoke, living product made from the patient's own cells. This narrative review summarises published evidence on how autologous CAR-T products are manufactured, where the process fails or slows, how quality and regulation are handled, and what the products cost health systems. Collection, activation, gene transfer, expansion and release testing each carry technical and logistical limits, and published economic models suggest value only under specific assumptions. Automation, shorter processes and allogeneic products are promising but unproven at scale. This review reports no new data, and cost evidence is largely modelled.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.